for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adamas Pharmaceuticals Inc

ADMS.OQ

Latest Trade

3.93USD

Change

-0.07(-1.75%)

Volume

39,951

Today's Range

3.88

 - 

4.06

52 Week Range

3.35

 - 

18.51

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.00
Open
3.99
Volume
39,951
3M AVG Volume
12.13
Today's High
4.06
Today's Low
3.88
52 Week High
18.51
52 Week Low
3.35
Shares Out (MIL)
27.77
Market Cap (MIL)
110.53
Forward P/E
-1.08
Dividend (Yield %)
--

Latest Developments

More

Adamas Pharmaceuticals Appoints Neil Mcfarlane As Chief Executive Officer

Adamas Pharmaceuticals Appoints Neil Mcfarlane As Chief Executive Officer

Adamas Reports Q2 Loss Per Share $0.90

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Industry

Biotechnology & Drugs

Contact Info

1900 Powell St Ste 1000

+1.510.4503554

https://adamaspharma.com/

Executive Leadership

David L. Mahoney

Lead Independent Chairman of the Board

Neil McFarlane

Chief Executive Officer, Director

Alfred G. Merriweather

Chief Financial Officer

Christopher B. Prentiss

Chief Accounting Officer

Jennifer J Rhodes

Chief Compliance Officer, General Counsel, Corporate Secretary, Chief Business Officer

Key Stats

2.27 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-2.770

2017

-3.970

2018

-4.870

2019(E)

-3.691
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.29
Price To Book (MRQ)
2.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
289.27
LT Debt To Equity (MRQ)
285.56
Return on Investment (TTM)
-54.33
Return on Equity (TTM)
-48.93

Latest News

Latest News

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment

* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia

* ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

BRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers

* ADAMAS PHARMACEUTICALS SAYS AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING

BRIEF-Adamas Q4 Loss Per Share $1.27

* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017

BRIEF-Adamas Announces Proposed Public Offering Of Common Stock

* ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results

BRIEF-Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals

* Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing Source text (http://bit.ly/2zY2CVE) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma

* Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing Source text : (http://bit.ly/2lnW6oI) Further company coverage:

BRIEF-Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI

* FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI Source text for Eikon: Further company coverage:

BRIEF-Adamas appoints Mardi C. Dier to its board of directors

* Adamas appoints Mardi C. Dier to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica

* Adamas Pharmaceuticals says on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing

BRIEF-Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals

* Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing Source text: [http://bit.ly/2xSxczx] Further company coverage:

BRIEF-Adamas announces topline phase 1b data of ADS-4101 for the treatment of partial onset seizures in epilepsy

* Adamas announces topline phase 1b data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy

Adamas Pharma secures approval for Parkinson's dyskinesia drug

The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading.

BRIEF-Adamas announces FDA approval of Gocovri as first and only medication for dyskinesia treatment in Parkinson’s disease patients

* Adamas Pharmaceuticals Inc - Gocovri is expected to be available in Q4, and formally launched in Jan 2018 Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals Q2 loss per share $0.93

* Adamas reports recent achievements and second quarter 2017 financial results

BRIEF-Adamas Pharma says Alfred G. Merriweather appointed CFO

* Says cfo william j. Dawson to retire Source text for Eikon: Further company coverage:

BRIEF-Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology

* Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up